Latest Breaking News On - Call webcast - Page 9 : vimarsana.com

Mr Cooper Group Reports Second Quarter 2023 Results

Reported total net income of $142 million including other mark-to-market of $61 million, equivalent to ROCE of 14.1% Book value per share and tangible book value per share increased to $61.02 and.

Jay brayChris marshallCooper groupCooper group incVice chairmanCall webcastMonths ended juneMonths ended marchCommon equity

Village Farms International to Report Second Quarter 2023 Financial Results on Wednesday,

VANCOUVER, British Columbia, July 24, 2023 (GLOBE NEWSWIRE) Village Farms International, Inc. (“Village Farms” or the “Company”) (NASDAQ: VFF) today announced it will host a conference call to discuss

British columbiaUnited kingdomUnited statesRose lifescienceLawrence chamberlainPure sunfarms incSecurities exchangeVillage farms international incUnited states department of agricultureVillage farms internationalRose lifescience incDrug administrationHealth botanicalsFarms internationalWednesday augustVillage farms second quarter

Adeia to Release Second Quarter 2023 Financial Results on August 7, 2023

Adeia to Release Second Quarter 2023 Financial Results on August 7, 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Chris chaneyviceAdeia incCall webcastInvestor contactChaneyvice president

Village Farms International Reports Financial Results for First Quarter 2023

Canadian Cannabis Business Maintains Number Two Market Share Position Nationally, Including Number Two Position in QuebecCanadian Cannabis Retail Branded Sales Increase 40% Year-Over-Year, Again. | May 10, 2023

United kingdomUnited statesBritish columbiaMichael degiglioRose lifescienceLawrence chamberlainRose lifescience incVillage farms international incCompany formUnited states department of agricultureCompany consolidated financial statementsSecurities exchangePure sunfarms incHealth botanicalsInternational cannabisVillage farms international

Aptose Reports Results for the First Quarter 2023

08.05.2023 - ─ Tuspetinib Dose Escalation and Dose Exploration Trial Completed and Delivered Clinical Responses as Monotherapy Over Four Dose Levels in Very Difficult to Treat AML Patient Populations ─ ─ Doublet of Tuspetinib and Venetoclax Dosing Underway for .

United statesTuspetinib monotherapyAptose biosciencesSusan pietropaoloAmerican society of hematologyEuropean school of haematologyExchange commissionDrug administrationAptose biosciences incCorporate communications investor relationsEuropean hematology associationBrisk enrollmentDoublet armsClinical activity already notedTuspetinib superior safety profile continuesChief executive